ACAD
31.07
-0.15
-0.48%
AEMD
0.25
-0.01
-4.48%
APRI
1.42
+0.09
+6.99%
ARNA
4.5
-0.06
-1.32%
ATEC
1.3
0.00
0.00%
CFN
59.59
+0.03
+0.04%
CNAT
5.98
+0.19
+3.28%
CRXM
0.21
0.00
0.00%
CYTX
0.48
0.00
0.00%
DXCM
61
+0.41
+0.68%
GNMK
13.3
+0.19
+1.45%
HALO
14.59
+0.44
+3.07%
ILMN
200.01
+2.15
+1.09%
INNV
0.21
+0.01
+4.95%
INO
8.5
0.00
0.00%
ISCO
0.06
+0.00
+7.83%
ISIS
69.88
+1.3
+1.90%
LGND
56.88
-0.54
-0.94%
LPTN
2.79
-0.1
-3.46%
MBVX
1.05
-0.1
-8.70%
MEIP
3.84
+0.12
+3.23%
MNOV
3.8
+0.01
+0.26%
MRTX
21.34
+0.88
+4.30%
MSTX
0.43
-0.02
-3.98%
NBIX
34.29
+0.9
+2.70%
NUVA
47.28
+0.81
+1.74%
ONCS
0.37
-0.02
-5.19%
ONVO
6.68
+0.19
+2.93%
OREX
5.34
-0.16
-2.82%
OTIC
31.75
+0.02
+0.06%
QDEL
24.45
+0.09
+0.37%
RCPT
112.71
-0.36
-0.32%
RGLS
18.63
+0.97
+5.49%
RMD
63.09
-0.23
-0.36%
SCIE
0.01
0.00
-9.60%
SPHS
0.47
+0.03
+6.59%
SRNE
10.73
+0.34
+3.27%
TROV
5.83
-0.02
-0.34%
VICL
1.05
+0.02
+1.46%
VOLC
17.98
+0.02
+0.11%
ZGNX
1.37
-0.02
-1.09%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Obalon Therapeutics Locks in $30 Million to Advance Weight-Loss Device

January 13, 2015 – 5:00 pm | Edit Post

Obalon Therapeutics Secures $30 Million to Advance Weight-Loss Device to Pivotal Trial in U.S.Company Expects to Complete Multi-Center Pivotal Trial in 2015SAN DIEGO, Jan. 14, 2015 /PRNewswire/ — Obalon Therapeutics, Inc. today announced the completio…

Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies

January 13, 2015 – 5:00 pm | Edit Post

SAN DIEGO, California and TORONTO, Ontario, Jan. 13, 2015 /PRNewswire/ – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, t…

TruMed Systems Graduates EvoNexus Incubator With $5.5M In Series B Funding

January 13, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 13, 2015 /PRNewswire-USNewswire/ –EvoNexus a San Diego-based incubator for technology startup companies, today announces the graduation of TruMed Systems, creators of the turnkey Vaccine Management Solution AccuVax.TruMed Systems was c…

Batu Biologics Appoints Biopharmaceutical Executive As Chairman Of The Board

January 13, 2015 – 5:00 pm | Edit Post

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors. We ar…

Vical Incorporated And AnGes, Inc. Announce Collaboration To Develop Therapy For Ebola Virus Disease

January 13, 2015 – 5:00 pm | Edit Post

SAN DIEGO and TOKYO, Jan. 14, 2015 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) and AnGes MG (Tokyo:4563) announced today that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients …

Isis Pharmaceuticals, Inc. Earns $7M for Advancing ISIS-SMN Rx In Children With Spinal Muscular Atrophy

January 13, 2015 – 5:00 pm | Edit Post

CARLSBAD, Calif., Jan. 14, 2015 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMN…

Human Longevity Inc. Signs Agreement With Genentech For Whole Genome Sequencing And Analysis Of Samples

January 13, 2015 – 5:00 pm | Edit Post

LA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ — Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced a multi-year agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to conduct whole genome sequencing of tens of thousands…

Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

January 13, 2015 – 4:45 pm | Edit Post
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

SAN DIEGO, California and TORONTO, Ontario, Jan. 13, 2015 /PRNewswire/ – Aptose
Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company
developing new therapeutics and molecular diagnostics that target the
underlying mechanisms of cancer, today announced dosing of the first
patient in its Phase 1b clinical study of APTO-253 in patients with
relapsed or refractory hematologic malignancies.  APTO-253 is a
first-in-class inducer of the Krüppel-like factor 4 (KLF4) tumor
suppressor gene, and the only clinical-stage compound targeted for
patients with suppressed KLF4 levels.

“Epigenetic suppression of the KLF4 gene has been reported as a key
transforming event in acute myeloid leukemia and high-risk
myelodysplastic syndromes, and Aptose is a pioneer in advancing KLF4
induction as a new therapeutic approach for the treatment of these
patient populations,” commented William G. Rice, Ph.D., Chairman,
President and CEO.

About the Study

The Phase 1b, multicenter, open-label, dose-escalation clinical trial of
APTO-253 is designed to assess the safety, tolerability,
pharmacokinetics and pharmacodynamic responses and efficacy of APTO-253
as a single agent.  APTO-253 will be administered twice weekly, over a
28-day cycle.  The study is expected to enroll up to 30 patients with
relapsed or refractory hematologic malignancies across two separate
dose-escalation arms: (a) up to 15 patients with acute myeloid leukemia
(AML) and high-risk myelodysplastic syndromes (MDS) patients, and (b)
up to 15 patients with lymphomas (Hodgkin and non-Hodgkin lymphoma) and
multiple myeloma. The study is designed to then transition to single-agent expansion
cohorts in AML and MDS, followed by combination studies. More information can be found at www.clinicaltrials.gov.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed
to discovering and developing personalized therapies addressing unmet
medical needs in oncology. Aptose is advancing new therapeutics focused
on novel cellular targets on the leading edge of cancer research,
coupled with companion diagnostics to identify the optimal patient
population for our products. Aptose’s small molecule cancer
therapeutics pipeline includes products designed to provide enhanced
efficacy with existing anti-cancer therapies and regimens without
overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ
under the symbol APTO and on the TSX under the symbol APS. For further
information, please visit www.aptosebiosciences.com.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws.  Such statements include,
but are not limited to, statements relating to the Company’s plans,
objectives, expectations and intentions and other statements including
words such as “continue”, “expect”, “intend”, “will”, “should”,
“would”, “may”, and other similar expressions. Such statements reflect
our current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by us are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements described in this press release. Such expressed or implied
forward looking statements could include, among others: our ability to
obtain the capital required for research and operations; the inherent
risks in early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the progress
of our clinical trials; our ability to find and enter into agreements
with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information
forms, annual reports and annual filings with Canadian securities
regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled “Risk Factors”
in our filings with Canadian securities regulators and the United
States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do not
intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure
you that such statements will prove to be accurate as actual results
and future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

January 13, 2015 – 4:45 pm | Edit Post
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

SAN DIEGO, California and TORONTO, Ontario, Jan. 13, 2015 /PRNewswire/ – Aptose
Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company
developing new therapeutics and molecular diagnostics that target the
underlying mechanisms of cancer, today announced dosing of the first
patient in its Phase 1b clinical study of APTO-253 in patients with
relapsed or refractory hematologic malignancies.  APTO-253 is a
first-in-class inducer of the Krüppel-like factor 4 (KLF4) tumor
suppressor gene, and the only clinical-stage compound targeted for
patients with suppressed KLF4 levels.

“Epigenetic suppression of the KLF4 gene has been reported as a key
transforming event in acute myeloid leukemia and high-risk
myelodysplastic syndromes, and Aptose is a pioneer in advancing KLF4
induction as a new therapeutic approach for the treatment of these
patient populations,” commented William G. Rice, Ph.D., Chairman,
President and CEO.

About the Study

The Phase 1b, multicenter, open-label, dose-escalation clinical trial of
APTO-253 is designed to assess the safety, tolerability,
pharmacokinetics and pharmacodynamic responses and efficacy of APTO-253
as a single agent.  APTO-253 will be administered twice weekly, over a
28-day cycle.  The study is expected to enroll up to 30 patients with
relapsed or refractory hematologic malignancies across two separate
dose-escalation arms: (a) up to 15 patients with acute myeloid leukemia
(AML) and high-risk myelodysplastic syndromes (MDS) patients, and (b)
up to 15 patients with lymphomas (Hodgkin and non-Hodgkin lymphoma) and
multiple myeloma. The study is designed to then transition to single-agent expansion
cohorts in AML and MDS, followed by combination studies. More information can be found at www.clinicaltrials.gov.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed
to discovering and developing personalized therapies addressing unmet
medical needs in oncology. Aptose is advancing new therapeutics focused
on novel cellular targets on the leading edge of cancer research,
coupled with companion diagnostics to identify the optimal patient
population for our products. Aptose’s small molecule cancer
therapeutics pipeline includes products designed to provide enhanced
efficacy with existing anti-cancer therapies and regimens without
overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ
under the symbol APTO and on the TSX under the symbol APS. For further
information, please visit www.aptosebiosciences.com.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws.  Such statements include,
but are not limited to, statements relating to the Company’s plans,
objectives, expectations and intentions and other statements including
words such as “continue”, “expect”, “intend”, “will”, “should”,
“would”, “may”, and other similar expressions. Such statements reflect
our current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by us are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements described in this press release. Such expressed or implied
forward looking statements could include, among others: our ability to
obtain the capital required for research and operations; the inherent
risks in early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the progress
of our clinical trials; our ability to find and enter into agreements
with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information
forms, annual reports and annual filings with Canadian securities
regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled “Risk Factors”
in our filings with Canadian securities regulators and the United
States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do not
intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure
you that such statements will prove to be accurate as actual results
and future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

UC San Diego School of Medicine Named One of Nation’s Top Residency Programs

January 13, 2015 – 12:37 pm | Edit Post

UC San Diego School of Medicine was today named one of the nation’s top residency training programs in 10 specialties by Doximity. The Doximity report included more than 50,000 peer nominations from board-certified US physicians, and evaluated 3,691 residency training programs across 20 specialties.